Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SHSC:2196 Stock Report

Market Cap: HK$67.4b

Shanghai Fosun Pharmaceutical (Group) Valuation

Is 2196 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2196 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2196 (HK$14) is trading above our estimate of fair value (HK$6.39)

Significantly Below Fair Value: 2196 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2196?

Key metric: As 2196 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2196. This is calculated by dividing 2196's market cap by their current earnings.
What is 2196's PE Ratio?
PE Ratio33.1x
EarningsCN¥2.11b
Market CapCN¥62.77b

Price to Earnings Ratio vs Peers

How does 2196's PE Ratio compare to its peers?

The above table shows the PE ratio for 2196 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.5x
1177 Sino Biopharmaceutical
25.7x12.9%HK$59.5b
1093 CSPC Pharmaceutical Group
10.7x2.7%HK$59.1b
3692 Hansoh Pharmaceutical Group
21.8x2.7%HK$110.3b
3320 China Resources Pharmaceutical Group
8x7.3%HK$32.6b
2196 Shanghai Fosun Pharmaceutical (Group)
33.1x30.1%HK$62.8b

Price-To-Earnings vs Peers: 2196 is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the peer average (16.6x).

Price to Earnings Ratio vs Industry

How does 2196's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
2196 33.1xIndustry Avg. 8.0xNo. of Companies5PE0612182430+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2196 is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the Hong Kong Pharmaceuticals industry average (8x).

Price to Earnings Ratio vs Fair Ratio

What is 2196's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2196 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.1x
Fair PE Ratio18.7x

Price-To-Earnings vs Fair Ratio: 2196 is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the estimated Fair Price-To-Earnings Ratio (18.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Innovent Biologics

HK$60.8b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$38.40

7D

7.0%

1Y

-15.6%

3SBio

HK$13.1b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.61

7D

-2.3%

1Y

-25.8%

United Laboratories International Holdings

HK$18.2b

An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.

3933

HK$10.02

7D

1.8%

1Y

26.7%